Format

Send to

Choose Destination
Mult Scler. 2015 Jan;21(1):22-34. doi: 10.1177/1352458514549398. Epub 2014 Oct 24.

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Author information

1
Department of Neurology and Center for Neuropsychiatry, Medical Faculty, Heinrich-Heine University, Germany hans-peter.hartung@uni-duesseldorf.de.
2
Department of Neurology and Center for Neuropsychiatry, Medical Faculty, Heinrich-Heine University, Germany.
3
Moscow City Center of Multiple Sclerosis, Russian Federation, Russia.

Abstract

Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II). Important adverse events were infusion-associated reactions, serious infections and autoimmune events. A safety monitoring program allowed for early detection and management of autoimmune events. Recommendations for the monitoring of adverse events are made. Alemtuzumab's mechanism of action, pharmacodynamics and opportunities for future research are discussed.

KEYWORDS:

Alemtuzumab; CD52; monoclonal antibody; multiple sclerosis

PMID:
25344374
PMCID:
PMC4361497
DOI:
10.1177/1352458514549398
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center